Objective : To investigate the clinical value of microcirculation dredging therapy (MD for short) for the type 2 diabetic nephropathy patients (DN). Method : 94 early stage DN patients were divided into conventional group (C Group)and dredging treatment group (T Group). For the C Group, the conventional treatment method of controlling blood glucose, blood pressure and blood lipid was applied, and for the T Group ,in addition to the conventional treatment as applied to the C Group, Dextran 40 Glucose injection and mailuoning was injected by intravenous drip, with concurrent oral administration of acetylsalicylic acid enterosoluble tables. Both groups were treated for a period of six minths. Results: Determination of both groups showed after the treatment as compared with those before the treatment, but T Group showedmore apparent decrease (P＜0.05-0. 001), the T Group showed apparently more reduction in fibrinogen(Fg) and platelet a-granule membrane protein (GMP -140) (P＜0. 001) as compared with the C Group (P＜ 0. 05-0. 001) ;after the treatment, the blood glucose, blood pressure and blood lipid were well controlledin both groups (P＜0. 05-0. 001), with no substantial difference between the two groups (P＞0.05). Theresults of regression analysis showed that there was a positive correlation between platelet GMP-140andurinary albumin (UAIb) (r=0. 5433, P＜0.01). Conclusion： For early stage DN patients, the MD therapymay further improve the renal function while controlling he blood glucose, blood pressure and blood lipid.
展开▼
